CHI3L1基因的（-131C→G）变异与胶质母细胞瘤风险及预后无关联。
No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis.
作者信息
Boisselier Blandine, Marie Yannick, El Hallani Soufiane, Kaloshi Gentian, Iershov Anton, Kavsan Vadym, Psimaras Dimitri, Thillet Joëlle, Hoang-Xuan Khe, Delattre Jean-Yves, Sanson Marc
机构信息
INSERM, U711, Biologie des Interactions Neurones & Glie, 75013, Paris, France.
出版信息
J Neurooncol. 2009 Sep;94(2):169-72. doi: 10.1007/s11060-009-9817-4. Epub 2009 Mar 3.
Expression of CHI3L1 (YKL-40) has been correlated with prognosis of glioblastoma. The variant allele (-131C-->G) of CHI3L1 promoter results in a lower transcription of CHI3L1. Therefore, we tested the hypothesis that the G variant could protect against the risk of gliomas or have a favorable prognostic impact. DNA from 296 glioblastoma patients and 190 controls were genotyped on the -131 allele. Tumor RNA was obtained from 108 patients for CHI3L1 transcript quantification. Neither genotype nor allele distribution differed between patients and controls. There was no significant difference in survival between the CC, CG, and GG patients despite the few GG patients tended to have a longer survival. There was no correlation between genotype and CHI3L1 expression in tumor samples. Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
几丁质酶3样蛋白1（YKL-40）的表达与胶质母细胞瘤的预后相关。几丁质酶3样蛋白1启动子的变异等位基因（-131C→G）导致几丁质酶3样蛋白1的转录降低。因此，我们检验了以下假设：G变异体可以预防胶质瘤风险或具有良好的预后影响。对296例胶质母细胞瘤患者和190例对照的DNA进行了-131等位基因基因分型。从108例患者中获取肿瘤RNA用于几丁质酶3样蛋白1转录本定量分析。患者和对照之间的基因型和等位基因分布均无差异。尽管GG患者较少且倾向于有更长的生存期，但CC、CG和GG患者之间的生存期无显著差异。肿瘤样本中的基因型与几丁质酶3样蛋白1表达之间无相关性。综合我们的数据表明，几丁质酶3样蛋白1启动子的变异等位基因（-131C→G）对生存期无显著影响，不是胶质母细胞瘤的预后因素。
Zotero 插件